For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and Attruby represents a significant advancement . These innovative therapies preserve the transthyretin protein, slowing its destructive build-up and alleviating the severity of the illness. People are now reporting benefits